Opendata, web and dolomites

MISTRAL SIGNED

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MISTRAL project word cloud

Explore the words cloud of the MISTRAL project. It provides you a very rough idea of what is the project "MISTRAL" about.

millions    boost    faced    expertise    full    science    immune    applicable    despite    web    host    inform    software    health    critical    interventions    accessible    datasets    disorders    public    microbiome    eastern    infection    discover    interpretations    accelerated    diseases    clinical    acquisition    team    successful    antimicrobial    tool    hiv    inflammation    streamlining    2010    discoveries    mitigate    stratify    living    acquiring    human    biomarkers    efficacy    immunotherapies    repository    pandemic    complementary    immunotherapy    soaring    suggest    incorporated    27    60    drug    cloud    viral    irreversibly    patient    antiretroviral    systemic    cancer    outcomes    rationally    resolved    made    aging    curated    designed    treatment    continues    chronic    class    resistance    therapeutic    outcome    automate    regions    complications    beings    benefit    ideal    world    biomarker    mechanistically    mistral    aids    brings    risk    purposes    smes    impacts    innovations    gut    infections    validate    unlock    closer    deaths    stratification    cure    mankind   

Project "MISTRAL" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA 

Organization address
address: CARRETERA DE CANYET
city: BARCELONA
postcode: 8916
website: www.irsicaixa.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 9˙994˙383 €
 EC max contribution 9˙994˙383 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA ES (BARCELONA) coordinator 3˙967˙500.00
2    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 1˙490˙833.00
3    REGION HOVEDSTADEN DK (HILLEROD) participant 1˙017˙611.00
4    UNIVERSITE D'AIX MARSEILLE FR (Marseille) participant 730˙470.00
5    CASE WESTERN RESERVE UNIVERSITY CORPORATION US (CLEVELAND OHIO) participant 727˙787.00
6    AELIX THERAPEUTICS SL ES (BARCELONA) participant 534˙978.00
7    FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA ES (BARCELONA) participant 448˙021.00
8    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 351˙762.00
9    ASPHALION SL ES (BARCELONA) participant 316˙187.00
10    PROJECTE DELS NOMS - HISPANOSIDA ASOCIACION ES (BARCELONA) participant 236˙737.00
11    VEDANTA BIOSCIENCES INC US (WILMINGTON) participant 172˙493.00

Map

 Project objective

The HIV/AIDS pandemic continues to be one of the major health challenges ever faced by mankind. Far from being resolved, HIV is soaring in Eastern Europe (60% increase in new infections and 27% increase in deaths since 2010) and other regions of the world despite increasing access to antiretroviral treatment. There is emerging evidence that the human microbiome impacts some of the most important clinical aspects of HIV-1 infection, including immune disorders, chronic inflammation and accelerated aging. Work in other viral diseases and cancer immunotherapy suggest a critical role of the human microbiome also in the outcome of immune therapeutic interventions in HIV-1 infection. The MISTRAL project brings together a team of world-class HIV and microbiome researchers and SMEs with ideal complementary knowledge and expertise. This team will work to discover and validate novel gut microbiome biomarkers to inform rationally-designed, mechanistically-driven interventions on the gut microbiome to mitigate HIV-1 acquisition, systemic inflammation, chronic clinical complications, antimicrobial drug resistance, and boost the efficacy of HIV cure immunotherapies. Integrated and curated large microbiome and host datasets generated during the execution of the project will be made public through a freely accessible, specifically-dedicated web-based repository. Biomarker discoveries will be incorporated into a cloud-based software tool that will automate microbiome analyses and interpretations, thus streamlining patient stratification for clinical and research purposes. If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, and will produce novel concepts and technical innovations applicable to other human diseases. By doing that, MISTRAL will help to unlock the full clinical potential of the human microbiome to stratify patient outcomes and will irreversibly bring microbiome science closer to clinical practice.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MISTRAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MISTRAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More